利匹韦林抗人类免疫缺陷病毒转换治疗的效果和安全性  

Efficacy and safety of Rilpivirine for anti-human immunodeficiency virus conversion therapy

作　　者：张长平[1] 马燕[1] 朱晓虹[1] ZHANG Chang-ping;MA Yan;ZHU Xiao-hong(Department of Pharmacy,Beijing Youan Hospital,Capital Medical University,Beijing 100069,China)

机构地区：[1]首都医科大学附属北京佑安医院药学部,北京100069

出　　处：《临床药物治疗杂志》2021年第3期26-30,共5页Clinical Medication Journal

摘　　要：目的探讨利匹韦林(RPV)抗人类免疫缺陷病毒(HIV)转换治疗的效果和安全性。方法回顾性分析2019年3月至2020年9月在首都医科大学附属北京佑安医院接受抗逆转录病毒治疗的51例HIV感染者/获得性免疫缺陷综合征患者临床资料,比较RPV转换前后HIV病毒载量、CD4^(+)T细胞计数、转氨酶、血脂、肌酐(Cr)值。结果41例患者由依非韦伦转换为RPV,10例患者由洛匹那韦/利托那韦转换为RPV。转换前后患者病毒抑制率分别为94.12%与98.04%,CD4^(+)T细胞数分别为(591±194)个/μL与(677±236)个/μL;转换后患者甘油三酯、总胆固醇异常率显著下降,低密度脂蛋白胆固醇异常率也有所下降,高密度脂蛋白胆固醇异常率呈增长趋势,转氨酶无明显变化,Cr值有所上升。结论转换治疗选择RPV,疗效明确且安全性总体较好。Objective To investigate the efficacy and safety of Rilpivirine(RPV)conversion therapy anti-human immunodeficiency virus(HIV).Methods The clinical data of 51 patients with HIV infection/acquired immunodeficiency syndrome(AIDS)who received antiretroviral therapy(ART)in Beijing Youan Hospital,Capital Medical University from March 2019 to September 2020 were retrospectively analyzed.Compare the difference between before and after the RPV conversion therapy HIV load(VL),CD4^(+)T cell counts,transaminase,blood lipids,creatinine of HIV/AIDS patients.Results 41 cases,converted from Efavirenz to RPV;and 10 cases,converted from Lopinavir/Ritonavir to RPV.The rate of viral suppressions were 94.12%and 98.04%before and after conversion therapy;the number of CD4^(+)T cells were(591±194)cells/μL and(677±236)cells/μL.After conversion,the abnormality rate of triglycerides and total cholesterol decreased significantly,and the abnormality of low density lipoprotein-cholesterol also decreased,but the abnormality of high density lipoprotein-cholesterol showed an increasing trend.There was no significant change in transaminase.The creatinine value increased.Conclusion The ART regimens can select RPV for conversion therapy,the efficacy and safety of which is generally good.

关 键 词：获得性免疫缺陷综合征 抗逆转录病毒治疗 转换治疗 利匹韦林 

分 类 号：R512.91[医药卫生—内科学]